InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Scanlon Meghan, Vice-Présidente Senior, Présidente Urologie Santé Pelvique et Administratrice. Director active across 2 companies, notably Boston Scientific CORP. In total, 13 disclosures have been recorded. History available since 1 May 2021. The latest transaction was filed on 17 May 2024 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Scanlon Meghan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
42,113 sharesCommon StockSEC:0000950170-25-056369:0
15,906 shares0Common StockSEC:0001610717-24-000251:0
8,361 shares0Common StockSEC:0001610717-23-000056:0
2,062 shares0Common StockSEC:0001225208-22-006331:0
17,846 shares0Common StockSEC:0001567619-22-008111:0
1,019 shares0Common StockSEC:0001225208-22-003868:0
779 shares0Common StockSEC:0001225208-22-003088:0
1,583 shares0Common StockSEC:0001225208-22-002933:0
1,108 shares0Common StockSEC:0001225208-22-002699:0
13,850 shares@ US$23.4153.5% of flowCommon StockSEC:0001225208-21-010901:0
855 shares0Common StockSEC:0001225208-21-010279:0
16,450 shares@ US$17.2646.5% of flowCommon StockSEC:0001225208-21-009606:0
2,061 shares0Common StockSEC:0001225208-21-007475:0
13 of 13 declarations
About Scanlon Meghan
Meghan Scanlon is an executive at BOSTON SCIENTIFIC CORP.
